Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer

Sulman, Erik P.; Komaki, Ritsuko; Klopp, Ann H.; Cox, James D.; Chang, Joe Y.
January 2009
Radiation Oncology;2009, Vol. 4, p1
Academic Journal
Background: Controversy still exists regarding the long-term outcome of patients whose uninvolved lymph node stations are not prophylactically irradiated for non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. To determine the frequency of elective nodal failure (ENF) and in-field failure (IFF), we examined a large cohort of patients with NSCLC staged with positron emission tomography (PET)/computed tomography (CT) and treated with 3-dimensional conformal radiotherapy (3D-CRT) that excluded uninvolved lymph node stations. Methods: We retrospectively reviewed the records of 115 patients with non-small cell lung cancer treated at our institution with definitive radiation therapy with or without concurrent chemotherapy (CHT). All patients were treated with 3D-CRT, including nodal regions determined by CT or PET to be disease involved. Concurrent platinum-based CHT was administered for locally advanced disease. Patients were analyzed in follow-up for survival, local regional recurrence, and distant metastases (DM). Results: The median follow-up time was 18 months (3 to 44 months) among all patients and 27 months (6 to 44 months) among survivors. The median overall survival, 2-year actuarial overall survival and disease-free survival were 19 months, 38%, and 28%, respectively. The majority of patients died from DM, the overall rate of which was 36%. Of the 31 patients with local regional failure, 26 (22.6%) had IFF, 5 (4.3%) had ENF and 2 (1.7%) had isolated ENF. For 88 patients with stage IIIA/B, the frequencies of IFF, any ENF, isolated ENF, and DM were 23 (26%), 3 (9%), 1 (1.1%) and 36 (40.9%), respectively. The comparable rates for the 22 patients with early stage nodenegative disease (stage IA/IB) were 3 (13.6%), 1(4.5%), 0 (0%), and 5 (22.7%), respectively. Conclusion: We observed only a 4.3% recurrence of any ENF and a 1.7% recurrence of isolated ENF in patients with NSCLC treated with definitive 3D-CRT without prophylactic irradiation of uninvolved lymph node stations. Thus, distant metastasis and IFF remain the primary causes of treatment failure and cancer death in such patients, suggesting little value of ENI in this cohort.


Related Articles

  • 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eschmann, Susanne Martina; Friedel, Godehard; Paulsen, Frank; Reimold, Matthias; Hehr, Thomas; Budach, Wilfried; Langen, Heinz-Jakob; Bares, Roland // European Journal of Nuclear Medicine & Molecular Imaging;Apr2007, Vol. 34 Issue 4, p463 

    The aim of this study was to evaluate FDG-PET for assessment of therapy response and for prediction of patient outcome after neo-adjuvant radio-chemotherapy (NARCT) of advanced non-small cell lung cancer (NSCLC). Seventy patients with histologically proven stage III NSCLC underwent FDG-PET...

  • Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Nestle, Ursula; Schaefer-Schuler, Andrea; Kremp, Stephanie; Groeschel, Andreas; Hellwig, Dirk; Rübe, Christian; Kirsch, Carl-Martin // European Journal of Nuclear Medicine & Molecular Imaging;Apr2007, Vol. 34 Issue 4, p453 

    FDG PET is increasingly used in radiotherapy planning. Recently, we demonstrated substantial differences in target volumes when applying different methods of FDG-based contouring in primary lung tumours (Nestle et al., J Nucl Med 2005;46:1342–8). This paper focusses on FDG-positive...

  • Accuracy of PET/CT with FDG in mediastinal lymph node staging of patients with NSCLC. Pelosi, E.; Billè, A.; Skanjeti, A.; Arena, V.; Ardissone, F. // Health (1949-4998);Mar2010, Vol. 2 Issue 3, p204 

    PET/CT and contrast enhancement CT (CECT) are the two fundamental non-invasive exams in the preoperative staging of patients with non small cell lung cancer (NSCLC). In the staging of the mediastinum, recent studies show that PET is more accurate than CECT, with an average sensitivity and...

  • Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Cuaron, John; Dunphy, Mark; Rimner, Andreas // Frontiers in Oncology;Jan2013, Vol. 3, p1 

    The integral role of positron-emission tomography (PET) using the glucose analog tracer fluorine-18 fluorodeoxyglucose (FDG) in the staging of non-small cell lung cancer (NSCLC) is well established. Evidence is emerging for the role of PET in response assessment to neoadjuvant therapy,...

  • The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer. Fangfang Du; Zhiyong Yuan; Jun Wang; Lujun Zhao; Qingsong Pang; Liqun Gong; Changli Wang; Ping Wang // Chinese Journal of Lung Cancer;Nov2009, Vol. 12 Issue 11, p1164 

    Background and objective The clinical value of postoperative radiotherapy (PORT) in stage N2 nonsmall- cell lung cancer (NSCLC) is controversy. The aim of this study is to analyze the efficacy of PORT in subgroup of stage N2 NSCLC, which can help clinicians to choose proper patients for PORT....

  • Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan Gómez-Caro, Abel; Garcia, Samuel; Reguart, Noemí; Arguis, Pedro; Sanchez, Marcelo; Gimferrer, Josep M.; Marrades, Ramon; Lomeña, Francisco // European Journal of Cardio-Thoracic Surgery;May2010, Vol. 37 Issue 5, p1168 

    Abstract: Objective: This study sought to assess the real incidence of pN2 among patients with non-small-cell lung cancer (NSCLC) (cN0) with negative mediastinal uptake of 2-deoxy-2-(18F)-fluoro-o-glucose (FDG). Methods: During 30 consecutive months (January 2007–May 2009), all patients...

  • Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non--Small-Cell Lung Cancer. Gould, Michael K.; Kuschner, Ware G.; Rydzak, Chara E.; Maclean, Courtney C.; Demas, Anita N.; Shigemitsu, Hidenobu; Chan, Jo Kay; Owens, Douglas K. // Annals of Internal Medicine;12/2/2003, Vol. 139 Issue 11, p879 

    Purpose: To compare the diagnostic accuracy of computed tomography (CT) and positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in patients with non -- small-cell lung cancer and to determine whether test results are conditionally dependent (the...

  • Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria? Casiraghi, Monica; Travaini, Laura L.; Maisonneuve, Patrick; Tessitore, Adele; Brambilla, Daniela; Agoglia, Bernardo G.; Guarize, Juliana; Spaggiari, Lorenzo // European Journal of Cardio-Thoracic Surgery;Apr2011, Vol. 39 Issue 4, pe38 

    Abstract: Objective: The introduction of modern staging systems such as computed tomography (CT) and positron emission tomography/CT (PET/CT) with fluorodeoxyglucose ([18F]FDG) has increased the detection of small peripheral lung cancers at an early stage. We analyzed the behavior of...

  • Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma. Hofman, Michael; Smeeton, Nigel; Rankin, Sheila; Nunan, Tom; O’Doherty, Michael // European Journal of Nuclear Medicine & Molecular Imaging;Feb2009, Vol. 36 Issue 2, p194 

    Error and variation in reporting remains one of the weakest features of clinical imaging despite enormous technological advances in nuclear medicine and radiology. The aim of this study was to evaluate agreement amongst experienced readers in staging non-small-cell lung cancer (NSCLC) with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics